Kiromic Biopharma Inc (KRBP) - Total Assets
Based on the latest financial reports, Kiromic Biopharma Inc (KRBP) holds total assets worth $8.54 Million USD as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Kiromic Biopharma Inc - Total Assets Trend (2018–2024)
This chart illustrates how Kiromic Biopharma Inc's total assets have evolved over time, based on quarterly financial data. Also see market value of Kiromic Biopharma Inc for the company's overall valuation and market capitalisation.
Kiromic Biopharma Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Kiromic Biopharma Inc's total assets of $8.54 Million consist of 38.6% current assets and 61.4% non-current assets. Review debt load of Kiromic Biopharma Inc to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Kiromic Biopharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Kiromic Biopharma Inc (KRBP) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kiromic Biopharma Inc's current assets represent 38.6% of total assets in 2024, a decrease from 64.0% in 2018.
- Cash Position: Cash and equivalents constituted 13.3% of total assets in 2024, down from 43.9% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Kiromic Biopharma Inc Competitors by Total Assets
Key competitors of Kiromic Biopharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Vaxcyte Inc
NASDAQ:PCVX
|
USA | $3.14 Billion |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $1.11 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.16 Billion |
Kiromic Biopharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.16 | 0.22 | 3.67 |
| Quick Ratio | 0.16 | 0.22 | 3.64 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-17.60 Million | $-15.95 Million | $2.37 Million |
Kiromic Biopharma Inc - Advanced Valuation Insights
This section examines the relationship between Kiromic Biopharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.55 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -29.8% |
| Total Assets | $8.54 Million |
| Market Capitalization | $214.93K USD |
Valuation Analysis
Below Book Valuation: The market values Kiromic Biopharma Inc's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Kiromic Biopharma Inc's assets decreased by 29.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Kiromic Biopharma Inc (2018–2024)
The table below shows the annual total assets of Kiromic Biopharma Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $8.54 Million | -29.78% |
| 2023-12-31 | $12.17 Million | +1.68% |
| 2022-12-31 | $11.97 Million | -61.06% |
| 2021-12-31 | $30.73 Million | +139.52% |
| 2020-12-31 | $12.83 Million | +383.65% |
| 2019-12-31 | $2.65 Million | +202.82% |
| 2018-12-31 | $876.00K | -- |
About Kiromic Biopharma Inc
Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, engages in the utilization of non-engineered an engineered allogeneic Gamma Delta T (GDT) cell technologies to develop therapies for solid tumors in the United States. The company's lead product candidate is the Deltacel-01, which is in Phase 1 clinical trial, in combination with low-dose targeted radiation for patients with non-s… Read more